Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging.
暂无分享,去创建一个
Wei Wang | Yunze Yang | Shaopeng Wang | Nongjian Tao | Yuyuan Tian | L. Yin | Yunze Yang | Shaopeng Wang | Wei Wang | Linliang Yin | Yan Guan | Fenni Zhang | Han Xu | Fenni Zhang | N. Tao | Yan Guan | Han Xu
[1] J. Benovic,et al. Modulation of the Arrestin-Clathrin Interaction in Cells , 1997, The Journal of Biological Chemistry.
[2] A. Maity,et al. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. , 2007, Cancer letters.
[3] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] Xiaobo Yu,et al. In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance , 2014, Scientific Reports.
[6] R. Corn,et al. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. , 2007, Analytical chemistry.
[7] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[8] Roy S Herbst,et al. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.
[9] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[10] Igor L. Medintz,et al. Quantum dot bioconjugates for imaging, labelling and sensing , 2005, Nature materials.
[11] R. Tsien,et al. The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.
[12] Yunze Yang,et al. Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. , 2012, Nature chemistry.
[13] C. Arteaga. Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.
[14] Jerry M Maniate,et al. Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.
[15] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[16] Peter Wiktor,et al. Measurement of Small Molecule Binding Kinetics on a Protein Microarray by Plasmonic-Based Electrochemical Impedance Imaging , 2014, Analytical chemistry.
[17] P M Harari,et al. Epidermal growth factor receptor inhibition strategies in oncology. , 2004, Endocrine-related cancer.
[18] N. Normanno,et al. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? , 2006, Endocrine-related cancer.
[19] M. Malmqvist,et al. BIACORE: an affinity biosensor system for characterization of biomolecular interactions. , 1999, Biochemical Society transactions.
[20] R. Herbst,et al. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. , 2002, Expert opinion on biological therapy.
[21] G. Adams,et al. Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.
[22] J. Grandis,et al. Signaling through the epidermal growth factor receptor during the development of malignancy. , 2004, Pharmacology & therapeutics.
[23] Aaron R. Halpern,et al. Near infrared surface plasmon resonance phase imaging and nanoparticle-enhanced surface plasmon resonance phase imaging for ultrasensitive protein and DNA biosensing with oligonucleotide and aptamer microarrays. , 2012, Analytical Chemistry.
[24] Sara Linse,et al. Methods for the detection and analysis of protein–protein interactions , 2007, Proteomics.
[25] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[26] H. Lenz,et al. EGFR, HER2 and VEGF Pathways , 2012, Drugs.
[27] M. Nakamoto,et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.
[28] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[29] F. Ciardiello. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents , 2012, Drugs.
[30] E. Butcher. Can cell systems biology rescue drug discovery? , 2005, Nature Reviews Drug Discovery.
[31] D. Swinney. The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.
[32] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[33] S. Gan,et al. Enzyme immunoassay and enzyme-linked immunosorbent assay. , 2013, The Journal of investigative dermatology.
[34] Yuyuan Tian,et al. Charge-based detection of small molecules by plasmonic-based electrochemical impedance microscopy. , 2013, Analytical chemistry.
[35] R. Schasfoort,et al. Handbook of surface plasmon resonance , 2008 .
[36] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[37] Roy S Herbst,et al. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. , 2002, Seminars in oncology.
[38] Wei Wang,et al. Plasmonic imaging of protein interactions with single bacterial cells. , 2015, Biosensors & bioelectronics.
[39] Targeted therapy in non-small-cell lung cancer. , 2002, Oncology.
[40] Konstantin A Lukyanov,et al. Fluorescent proteins as a toolkit for in vivo imaging. , 2005, Trends in biotechnology.
[41] B. Schoeberl,et al. Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies , 2012, Molecular Cancer Therapeutics.
[42] B. Haab. Methods and applications of antibody microarrays in cancer research , 2003, Proteomics.
[43] C. Arteaga,et al. Tyrosine kinase inhibitors—ZD1839 (Iressa) , 2001, Current opinion in oncology.
[44] Aaron R. Halpern,et al. On-chip synthesis of protein microarrays from DNA microarrays via coupled in vitro transcription and translation for surface plasmon resonance imaging biosensor applications. , 2012, Journal of the American Chemical Society.
[45] M. Trevethick,et al. Ligand binding assays at equilibrium: validation and interpretation , 2010, British journal of pharmacology.
[46] R. Corn,et al. On-chip synthesis of RNA aptamer microarrays for multiplexed protein biosensing with SPR imaging measurements. , 2012, Langmuir : the ACS journal of surfaces and colloids.
[47] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[48] J. Baselga. Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.
[49] J. Baselga,et al. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.